Chemicals & Pharmaceuticals. EU Regulations 2026

Relevant regulations11on this page
in force8/ 11
Next key date30/12/2026EUDR

Overview

Chemicals and pharmaceuticals are among the most densely regulated industries in the EU. Beyond the core of chemicals and medicines law – REACH, CLP, marketing authorisation and GMP – companies are hit by almost every horizontal regulation: NIS2, because pharmaceutical companies belong to the health sector and chemical companies to a separate NIS2 sector; CBAM, because fertilisers and hydrogen are CBAM goods; and the sustainability and supply chain rules, because the industry is energy-intensive and sources raw materials worldwide.

Data obligations come on top: clinical trials and pharmacovigilance process health data, and the EHDS creates new access to health data for research and development.

The Most Important Regulations

RegulationWhat it means for chemicals and pharmaStatus / key date
NIS2Pharma: Annex I (health); chemicals: Annex IIDE since 06.12.2025, AT since 01.10.2026
CBAMImports of fertilisers and hydrogenDefinitive period since 01.01.2026
EUDRPalm oil, soy and rubber products listed in Annex Ifrom 30.12.2026
LkSG and CSDDDHuman rights and environment in the supply chain, incl. mercury, POPs and hazardous wasteLkSG since 2023, CSDDD from 26.07.2029
CSRD and EU TaxonomyReporting from 1,000 employees and EUR 450 million turnoverFinancial year 2027 (report 2028)
Product Liability DirectiveEasier burden of proof for claimants, no capsfor products from 09.12.2026
EHDSPharma as data holder and data userapplicable from 26.03.2027
AI ActAI in medical devices is high-risk under Annex Ifrom 02.08.2028
GDPRHealth data from trials and pharmacovigilancesince 25.05.2018
Whistleblower DirectiveInternal reporting channel from 50 employeessince 17.12.2023

NIS2: Pharma in the Health Sector, Chemicals in Annex II

The classification differs between the two industries:

  • Pharma: The health sector (Annex I) includes entities carrying out research and development of medicinal products and manufacturers of basic pharmaceutical products and preparations. Large companies are essential entities (‘particularly important’ in Germany) with proactive supervision and fines of at least EUR 10 million or 2% of worldwide turnover; medium-sized ones are important entities.
  • Chemicals: ‘Manufacture, production and distribution of chemicals’ is an Annex II sector. It covers manufacturers and distributors of substances and mixtures within the meaning of REACH and producers of articles made from them. Medium-sized and large companies are important entities.

Medium-sized means at least 50 employees, or more than EUR 10 million turnover and more than EUR 10 million balance sheet total. The obligations – registration, ten minimum measures, reporting of significant incidents within 24 hours, 72 hours and one month – also cover process control systems and laboratory IT.

Chemicals Law as the Foundation

Chemicals law is not covered in detail on this platform, but it shapes many of the other obligations:

  • REACH (Regulation (EC) No 1907/2006): registration of substances from 1 tonne per year (‘no data, no market’), authorisation and restriction. Suppliers of articles containing substances of very high concern (SVHC) above 0.1% weight by weight must inform their recipients.
  • CLP (Regulation (EC) No 1272/2008): classification, labelling and packaging of hazardous substances and mixtures.
  • Cross-links: The simplified DNSH criteria of the EU Taxonomy on pollution prevention concern chemicals in particular. The ecodesign regulation ESPR expressly excludes medicinal products.

Emissions and Raw Materials: CBAM and EUDR

CBAM covers fertilisers and hydrogen, among others. The de minimis threshold of 50 tonnes per year applies to fertilisers; hydrogen is always covered. Importers need authorisation as a CBAM declarant and verified emissions data from their producers, otherwise unfavourable default values apply. Goods originating in Switzerland are exempt.

The EUDR affects the industry through palm oil, soy and rubber and products made from them, insofar as they are listed in Annex I. The delegated act of July 2026 is set to add certain palm oil derivatives – check your customs codes against the version published in the Official Journal.

Supply Chain, Sustainability and Liability

  • LkSG: Besides human rights, the LkSG protects environmental positions from three conventions – mercury (Minamata), persistent organic pollutants (Stockholm) and hazardous waste (Basel). For chemicals, these are central risk areas.
  • CSRD and EU Taxonomy: After Omnibus I, only companies with more than 1,000 employees and EUR 450 million turnover report. The Taxonomy allows investments in low-emission processes to be shown as taxonomy-aligned.
  • Product liability: For products placed on the market after 9 December 2026, disclosure rights and presumptions in favour of claimants apply. German pharmaceutical liability under § 84 AMG remains as a special liability regime.

Data and AI: GDPR, EHDS, AI Act

Health data is a special category under the GDPR. The EHDS makes pharmaceutical companies data holders that provide certain data via the access body, and gives them access as data users to health data for research and AI training – mostly from 26 March 2029. Under the AI Act, AI in medical devices and in vitro diagnostics is high-risk under Annex I (from 2 August 2028).

Deadlines 2026/2027

DateWhat applies
since 01.10.2026NISG 2026 in Austria; registration by end of 2026
09.12.2026Transposition deadline of the Product Liability Directive
30.12.2026EUDR for medium-sized and large companies
01.02.2027CBAM certificates go on sale
19.03.2027Transposition deadline for the CSRD changes from the Omnibus
26.03.2027EHDS generally applicable
30.09.2027First annual CBAM declaration for 2026
02.12.2027AI Act: high-risk AI under Annex III
02.08.2028AI Act: AI in products under Annex I, e.g. medical devices
26.03.2029EHDS: most rules on secondary use

DACH Specifics

  • Germany: NIS2 has applied since 6 December 2025, with registration at the BSI. The Bundestag passed the transposition of the Product Liability Directive on 8 October 2026; promulgation is pending. The LkSG continues to apply until it is reformed.
  • Austria: NISG 2026 since 1 October 2026. As of October 2026, there was no ministerial draft for the new product liability rules. There is no supply chain act.
  • Switzerland: CBAM exemption for goods of Swiss origin. Operators of critical infrastructure – including in health – must report cyberattacks to the BACS within 24 hours. For REACH registration of substances supplied to the EU, Swiss manufacturers need an only representative in the EU or an EU importer.

Checklist

  • Clarify NIS2 classification per entity: health sector (Annex I) or chemicals (Annex II)
  • Include process control systems, laboratory IT and service providers in risk management
  • Record CBAM imports of fertilisers and hydrogen and request emissions data
  • Check palm oil, soy and rubber products against EUDR Annex I
  • Extend the LkSG risk analysis to mercury, POPs and hazardous waste
  • Review data protection concepts for trial and pharmacovigilance data with the EHDS in mind
  • Combine the whistleblowing system and the LkSG complaints procedure

Find out which regulations apply to your company with the regulation finder.

Check now: Which regulations affect your company?

Stay informed

Get information on new and updated EU regulations for your industry.

Frequently Asked Questions

Are pharmaceutical companies covered by NIS2?

Yes. Manufacturers of basic pharmaceutical products and pharmaceutical preparations and entities carrying out research and development of medicinal products belong to the health sector in Annex I. Large companies there are essential entities – 'particularly important' in Germany –, medium-sized companies are important entities.

Are chemical companies covered by NIS2?

Yes, if they are medium-sized or large. 'Manufacture, production and distribution of chemicals' is an Annex II sector. It covers manufacturers and distributors of substances and mixtures within the meaning of REACH and producers of articles made from them. They are important entities.

Does CBAM affect the chemical industry?

Yes, for imports of fertilisers and hydrogen, which are CBAM goods. The 50-tonne threshold does not apply to hydrogen – it is always covered. Certificates for imports from 2026 go on sale from 1 February 2027, and the first annual declaration is due by 30 September 2027.

Does the new Product Liability Directive apply to medicinal products?

The directive applies to all products placed on the market after 9 December 2026. It does not affect national special liability systems that already existed on 30 July 1985 – in Germany, this concerns pharmaceutical liability under § 84 of the Medicinal Products Act (AMG).

What does the EHDS mean for pharmaceutical companies?

Pharmaceutical companies are data holders that must make certain health data available via the national health data access body, and potential data users: with a data permit, they can use health data for research, development or AI training. Most rules on secondary use apply from 26 March 2029.

Is AI in drug research high-risk AI?

Not automatically. AI is high-risk mainly as a safety component or product under the EU product legislation listed in Annex I – including medical devices and in vitro diagnostics, with obligations from 2 August 2028 – and in the Annex III areas such as recruitment. In addition, the GDPR treats health data as a special category.